Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Smallpox

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Lymph node-targeted mRNA delivery of fine-tuned peptide-nanocomplexes for SARS-CoV-2 Vaccination.

Biomaterials·2026

Same author

Duration of vaccine-induced immunity following MMR2 vaccination in a measles and rubella-eliminated country.

International journal of epidemiology·2026

Same author

Effects of <i>Allium fistulosum</i> L. (Green Onion) Root and <i>Avena sativa</i> L. (Oat) Mixtures (WCO31) on the Height of Children: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Nutrients·2026

Same author

Correction: Cross-protective efficacy of NA-based mRNA vaccine candidates against seasonal and avian influenza viruses.

Frontiers in microbiology·2026

Same author

Cross-protective efficacy of NA-based mRNA vaccine candidates against seasonal and avian influenza viruses.

Frontiers in microbiology·2026

Same author

Application of luminescence-producing Mycobacterium tuberculosis strains for evaluating anti-tuberculosis drug and vaccine efficacy in vitro and in vivo.

BMC infectious diseases·2026

Search research articles

Related Experiment Video

Updated: Jul 8, 2026

Optimization of a Quantitative Micro-neutralization Assay

Optimization of a Quantitative Micro-neutralization Assay

Published on: December 14, 2016

Plaque reduction neutralization test for smallpox vaccines: Laboratory optimization and validation method for

Hyun-Jung Kong¹, You-Jin Kim¹, Dokeun Kim¹

¹Division of Infectious Disease Vaccine Research, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, CheongJu, Chungbuk, Republic of Korea.

Journal of Immunological Methods

|December 13, 2024

Summary

A validated plaque reduction neutralization test (PRNT) reliably measures vaccinia virus (VACV) neutralizing antibodies. This assay is crucial for evaluating new smallpox vaccines, ensuring public health preparedness against variola virus threats.

Keywords:

Neutralizing antibody PRNT Standardization Vaccinia virus Validation

More Related Videos

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses

Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses

Published on: November 21, 2023

Related Experiment Videos

Last Updated: Jul 8, 2026

Optimization of a Quantitative Micro-neutralization Assay

Optimization of a Quantitative Micro-neutralization Assay

Published on: December 14, 2016

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses

Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses

Published on: November 21, 2023

Area of Science:

Virology
Immunology
Public Health

Background:

Smallpox eradication was a public health success, but understanding vaccine-induced immunity remains incomplete.
Concerns about bioterrorism and smallpox reemergence necessitate advanced vaccine development.
Third-generation smallpox vaccines are under development, requiring robust efficacy assessment methods.

Purpose of the Study:

To develop, optimize, and validate a plaque reduction neutralization test (PRNT) for measuring vaccinia virus (VACV)-neutralizing antibodies.
To establish the PRNT as a reliable surrogate marker for assessing the efficacy of smallpox vaccines.
To ensure the bioanalytical validity of the PRNT methodology according to established guidelines.

Main Methods:

Optimization of the VACV PRNT50 assay, defining parameters such as virus concentration, neutralization time, overlay concentration, and incubation period.
Validation of the PRNT methodology using human serum samples from individuals vaccinated with a second-generation smallpox vaccine.
Assessment of assay performance using receiver-operating characteristic (ROC) curve analysis, sensitivity, specificity, intra-assay and inter-assay precision, robustness, and dilution linearity.

Main Results:

The optimized VACV PRNT50 assay demonstrated high performance with a cut-off point of 22.58.
Sensitivity and specificity assays showed favorable outcomes: 93.55% sensitivity and 93.75% specificity against VACV strain Western Reserve.
The PRNT exhibited 100% intra-assay and inter-assay precision and high accuracy across various antibody titers.

Conclusions:

The plaque reduction neutralization test (PRNT) is a validated and reliable method for quantifying VACV-neutralizing antibodies in human serum.
This validated PRNT serves as a critical tool for evaluating the immunogenicity and efficacy of novel smallpox vaccines.
The study supports the ongoing development and licensure of third-generation smallpox vaccines for public health security.